THE NEW ANTHRACYCLINE 4-DEMETHOXYDAUNORUBICIN BY ORAL ROUTE IN ADVANCED PRETREATED BREAST-CANCER AND MELANOMA - A PILOT-STUDY

Google Scholar
  • 1 January 1985
    • journal article
    • research article
    • Vol. 11  (2) , 127-131
Abstract
4-Demethoxydaunorubicin (4-DMDR) was administered orally at the dose of 15 mg/m2 daily for 3 consecutive days at 3 weekly intervals to 28 patients with advanced pretreated breast cancer and 9 patients with disseminated pretreated melanoma. A partial remission was observed in 6 out of 20 evaluable breast cancer patients (30%) for a median duration of 6 mo. and in 1 out of 7 evaluable patients with melanoma (14%) for a duration of 3 mo. Side-effects included leukopenia in 78% of patients (< 1000 wbc[white blood cell]/mm3 in 8%), nausea in 32% and mild vomiting in 16%. The preliminary results of this ongoing study on 4-DMDR administered orally show that the regimen is well tolerated in the majority of patients and that it has antitumor activity in advanced breast cancer.